 Connection
Andrew Morris to Drug Design
This is a "connection" page, showing publications Andrew Morris has written about Drug Design.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.214 |
|
|
|
-
Subramanian T, Ren H, Subramanian KL, Sunkara M, Onono FO, Morris AJ, Spielmann HP. Design and synthesis of non-hydrolyzable homoisoprenoid a-monofluorophosphonate inhibitors of PPAPDC family integral membrane lipid phosphatases. Bioorg Med Chem Lett. 2014 Sep 15; 24(18):4414-4417.
Score: 0.111
-
Mathews TP, Kennedy AJ, Kharel Y, Kennedy PC, Nicoara O, Sunkara M, Morris AJ, Wamhoff BR, Lynch KR, Macdonald TL. Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors. J Med Chem. 2010 Apr 08; 53(7):2766-78.
Score: 0.082
-
Albers HM, Dong A, van Meeteren LA, Egan DA, Sunkara M, van Tilburg EW, Schuurman K, van Tellingen O, Morris AJ, Smyth SS, Moolenaar WH, Ovaa H. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A. 2010 Apr 20; 107(16):7257-62.
Score: 0.021
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|